JW신약

067290KOSDAQ의약품 제조업

50.0 / 100

Reference Date: 2026-06-10

Financial Score24.5 / 40

News Sentiment12.5 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but PBR raises overvaluation concerns. Plunged 28.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

JW Shinapharm primarily engages in the manufacturing and sales of pharmaceuticals, building a systematic sales network through joint marketing with JW Chungwa Pharmaceutical. Its subsidiary, JW Crigen, specializes in cell therapy products. In 2024, the company achieved consolidated sales of 93 billion won and an operating profit of 10 billion won. Key products include antifungal medications, dermatological treatments, and internal medicine drugs.

Number of Employees

173people

Average Salary

69.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

5.48Industry Average 11.938.0Point

Half of industry avg (excellent)

PBR

1.85Industry Average 0.890.0Point

2.1x industry avg (risky)

ROE

46.53Industry Average 4.017.0Point

11.6x industry avg (excellent)

Debt Ratio

5.17Industry Average 12.436.5Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼11.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲25.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -11.2% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 1,343Won52-week high 2,48052-week low 1,294

1-month return0.0Point

1m -28.18% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-05-22
Neutral증권발행결과(자율공시)2026-05-22
Neutral증권발행결과(자율공시)2026-05-22
Neutral주요사항보고서(전환사채권발행결정)2026-05-21
Neutral주요사항보고서(자본으로인정되는채무증권발행결정)2026-05-21